1 May 2026Oral drugs
Mifepristone oral
Mifepristone guidance for termination of intra-uterine pregnancy up to 22 weeks when combined with misoprostol.
Prescription under medical supervision
This guide page is for structured reference only and does not replace a clinician, pharmacist, or emergency review. Dose choice, route choice, interactions, and safety decisions still need professional judgment.
Therapeutic action
Antiprogestogen.
Indications
Termination of intra-uterine pregnancy up to 22 weeks after the last menstrual period, in combination with misoprostol.
Forms and strengths
- 200 mg tablet.
Dose and duration
- 200 mg single dose, followed by the administration of misoprostol 1 to 2 days later.
Contra-indications, adverse effects, precautions
- Do not administer to patients with chronic adrenal failure or severe uncontrolled asthma.
- May cause gastrointestinal disturbances, vaginal bleeding, uterine contractions, and headache.
- Breast-feeding: no contra-indication for a single dose; avoid if multiple doses are required.
- Do not use mifepristone in ectopic or molar pregnancy.
Source
MSF Essential drugs practical guidelines (January 2026)
This page reproduces the structured reference information for this batch while leaving out the Storage and Remarks sections.
Rate this guide
Be the first to rate this guide.